Dogra Sunil, Shah Shikha, Gupta Manavi, Sharma Ayush, Chhabra Seema
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Indian Dermatol Online J. 2024 Oct 28;15(6):930-941. doi: 10.4103/idoj.idoj_449_24. eCollection 2024 Nov-Dec.
Abrocitinib is a novel oral small molecule which acts as a selective JAK-1 inhibitor. Currently approved for use in moderate-to-severe cases of atopic dermatitis, this drug is gaining a rapid impetus for its use across various inflammatory dermatoses for its selective downstream action on cytokines of the JAK-1 pathway. Its efficacy and safety in atopic dermatitis has been established in phase 3 clinical trials. The future implication of this drug will depend largely on feasibility and practical use in Indian scenario.
阿布昔替尼是一种新型口服小分子药物，作为一种选择性JAK-1抑制剂。该药物目前已获批用于治疗中度至重度特应性皮炎，因其对JAK-1途径细胞因子的选择性下游作用，在各种炎症性皮肤病中的应用正在迅速获得推动。其在特应性皮炎中的疗效和安全性已在3期临床试验中得到证实。这种药物未来的影响将在很大程度上取决于在印度的可行性和实际应用情况。
